Shifting Chemo Administration from Inpatient to Outpatient Setting Improves Care and Reduces Costs

Back to Package

Shifting Chemo Administration from Inpatient to Outpatient Setting Improves Care and Reduces Costs

ACCC 37th National Oncology Conference 

This educational activity is jointly provided by AXIS Medical Education and ACCC

This activity is supported by educational grants from Abbvie,  AstraZeneca, GlaxoSmithKline, Lilly and Pfizer, Inc.

Release Date: 10/16/2020

Expire Date: 10/15/2021

Estimated Time to Complete: 75 minutes

Target audience: Physicians, nurses, APPs, pharmacists, pharmacy technicians, cancer program administrators, practice administrators, quality managers

Overview: At the University of Arizona Cancer Center, Banner University Medical Center Tucson, a multidisciplinary team of physicians, pharmacy staff, finance specialists, social workers, nursing staff, and information technologists first identified chemotherapy regimens administered in the inpatient setting that could be safely administered in the outpatient setting, and then implemented a transition plan that included provider and patient education. Benefits included reduced inpatient medical resources and chemotherapy costs, decreased inpatient bed stay, lower infection rates, improved quality of life, and decreased overall cost of care—conservatively estimated at almost $6 million.

Learning Objectives:

At the end of this educational activity, participants should be able to:

  • Discuss why transitioning select chemotherapy regimens to the outpatient setting may be advantageous to cancer programs.
  • Adapt a transition plan to administer chemotherapy in the outpatient setting to lower infection rates, improve quality of life, and reduce cost of care.
  • Demonstrate metrics which may be used to document successful transition of select chemotherapy  regimens to the outpatient setting.


Ali McBride, PharmD, MS
Daniel Persky, MD
The University of Arizona Cancer Center
Banner University Medical Center Tucson
Tucson, AZ

Kerri Michalik, MHA, BSN
Vice President, Cancer Services
Geisinger Health System, Geisinger Cancer Institute


Accreditation Statement


In support of improving patient care, this activity has been planned and implemented by AXIS Medical Education and ACCC.  AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


This activity was planned by and for the healthcare team, and learners will receive 1.25 Interprofessional Continuing Education (IPCE) credit for learning and change.

Credit Designation for Physicians
AXIS Medical Education designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit Designation for Pharmacists
This knowledge-based activity is approved for 1.25 contact hours of continuing pharmacy education credit JA4008106-9999-20-068-H01-P.

Credit Designation for Nursing
AXIS Medical Education designates this continuing nursing education activity for 1.25 contact hours.
Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

Healthcare Executives
ACHE Qualified Education credit must be related to healthcare management (i.e., it cannot be clinical, inspirational, or specific to the sponsoring organization). It can be earned through educational programs conducted or sponsored by any organization qualified to provide education programming in healthcare management. Programs may be sponsored by ACHE, chapters, or other qualified sources, whether the programming is face-to-face or distance offerings (webinars, online seminars, self-study courses, etc.). You will receive a certificate of completion for 1.25 hours.

AXIS Contact Information
For information about the accreditation of this program please contact AXIS at

Disclosure of Conflicts of Interest
AXIS Medical Education requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

Name of Faculty or Presenter/Planner

Reported Financial Relationship

Ali McBride, PharmD, MS, BCOP

Consultant: Pfizer

Speaker's Bureau: Cohens

Daniel Persky, MD

Consultant: Bayer, Celgene, Cellectar Biosciences, Kymera Therapeutics,  Debiopharm (IDMC), MorphoSys and Sandoz.

Kerri Michalik, MHA, BSN

Nothing to disclose

The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity: 


Name of Planner/Manager/Reviewer

Reported Financial Relationship

Leigh Boehmer, PharmD, BCOP

Nothing to disclose

Christina Fuller, BSW

Nothing to disclose

Tom A. Gallo, MS, MDA

Nothing to disclose

Marilyn L. Haas-Haseman, PhD, RN, CNS, ANP-BC

Nothing to disclose

Monique J. Marino

Nothing to disclose

Rebecca McMahon

Nothing to disclose

Kerri Michalik, MHA, BSN

Nothing to disclose

Dee Morgillo, MEd., MT(ASCP), CHCP

Nothing to disclose

Barbara Schmidtman, PhD

Nothing to disclose


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Method of Participation and Request for Credit    

  • Attend/participate in the educational activity and review all course materials. 

To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately.

Ali McBride, PharmD, MS, BCOP

Clinical Coordinator of Hematology/Oncology, The University of Arizona Cancer Center

Ali McBride, PharmD, MS, BCOP, is the Clinical Coordinator of Hematology/Oncology at The University of Arizona Cancer Center. Currently serving on the Board of the Association of Community Cancer Centers (ACCC), Dr. McBride also chairs the Awards Selection Committee as well as the Corporate Development Committee. In addition to being a long-time ACCC member, Dr. McBride has been actively involved with the American Society of Health-System Pharmacists (ASHP) and the Hematology/Oncology Pharmacy Association (HOPA).

Dr. McBride has been working on oncology drug shortages and has testified on behalf of HOPA at the U.S. Food and Drug Administration (FDA) Drug Shortage Workshop; presented on behalf of ACCC at the Washington, D.C., Congressional Session; and was an invited member of the ASHP Drug Shortage Stakeholders Meeting. Dr. McBride is also actively involved with biosimilar regulation and the pharmacoeconomic impact of biosimilars into the U.S. marketplace. He currently serves as a working group member for HOPA on its biosimilar committee. In addition, he serves on the National Quality Forum Cancer Standing Committee. He has published numerous articles on drug shortages, oral chemotherapy adherence, stem cell transplant, and biosimilar implementation into the U.S. healthcare market.

Dan Persky

Associate Professor of Medicine

Dr. Persky serves as an Associate Professor of Medicine at the University of Arizona College of Medicine.  He is currently the Associate Director of the Clinical Investigations and Therapeutic Development Program.  He specializes in Hematology/Oncology, particularly in lymphoid malignancies, such as lymphoma, CLL, and others.

Dr. Persky received his bachelor's degree from Harvard University and his medical degree from the Albert Einstein College of Medicine in New York.  He completed his internship and residency at the Mayo Graduate School of Medicine in Rochester, Minnesota, then returned to New York to complete a three-year fellowship in Medical Oncology and Hematology at the Memorial Sloan-Kettering Cancer Center.

Dr. Persky is board certified by the American Board of Internal Medicine, sub-specialty of Medical Oncology.


3 Questions  |  1 attempt  |  0/3 points to pass
3 Questions  |  1 attempt  |  0/3 points to pass
Session Recording
Open to view video.
Open to view video.
3 Questions  |  3 attempts  |  3/3 points to pass
3 Questions  |  3 attempts  |  3/3 points to pass
12 Questions
CE Certificate
Up to 1.25 medical credits available  |  Certificate available
Up to 1.25 medical credits available  |  Certificate available